One year of complete clinical response in a metastatic breast cancer patient treated with a combination of lapatinib and gemcitabine

  • J. M. Gasent Blesa Hospital de Dénia. MarinaSalud. Partida de Benadlà s7n. Dénia. Alacant. Spain
  • J. B. Laforga Canales hospital de Dènia. Marina Salud. Dénia. Alacant. Spain
  • V. Alberola Candel Hospital Arnau de Vilanova. Valènica. Spain

Abstract

ABSTRACT

The treatment of metastatic breast cancer is challenging. We recently assisted in the development of targeted therapies (in combination with chemotherapy or as monotherapy) that have improved results for selected groups of patients. Lapatinib is a dual tyrosine kinase inhibitor that has shown efficacy in breast cancer. Consequently, its use has been approved, in combination with capecitabine, for the treatment of disease positive for the human epidermal growth factor receptor. Here, we present a case of complete clinical response to a combination of lapatinib and gemcitabine that was maintained for 1 year.

Author Biographies

J. M. Gasent Blesa, Hospital de Dénia. MarinaSalud. Partida de Benadlà s7n. Dénia. Alacant. Spain
Medical Oncology Department
J. B. Laforga Canales, hospital de Dènia. Marina Salud. Dénia. Alacant. Spain
Pathology Department. MD PhD
V. Alberola Candel, Hospital Arnau de Vilanova. Valènica. Spain
Medical Oncology
How to Cite
Gasent Blesa, J. M., Laforga Canales, J. B., & Alberola Candel, V. (1). One year of complete clinical response in a metastatic breast cancer patient treated with a combination of lapatinib and gemcitabine. Current Oncology, 17(2), 64-68. https://doi.org/10.3747/co.v17i2.422
Section
Case Report